Unjoni Ewropea - Malti - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - infezzjonijiet akkwistati mill-komunità - antibatteriċi għal użu sistemiku, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 u 5. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - qutavina is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

omrix biopharmaceuticals n. v. - fibrinoġen uman, trombina umana - hemostasi, kirurġiċi - sustanzi kontra l-emorraġija - evicel jintuża bħala kura ta 'appoġġ fil-kirurġija fejn it-tekniki kirurġiċi standard mhumiex biżżejjed, għal titjib fl-emostasi. evicel huwa wkoll indikat bħala appoġġ għas-sutura għall-emostażi f'kirurġija vaskulari.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international bv - azagly-nafarelin - ormoni u analogi pitwitarji u ipotalamiċi - dogs; salmonidae (salmonid fish) - female salmonid fish bħas-salamun tal-atlantiku (salmo salar), trota tal-qawsalla (oncorhynchus mykiss), trota kannella (salmo trutta) u l-charr arktiku (salvelinus alpinus)induzzjoni u sinkronizzazzjoni ta 'l-ovulazzjoni għall-produzzjoni ta' bajd bil-għajn u ħut żgħir. klieb (klieb)l-prevenzjoni tal-funzjoni gonadali fil-klieb nisa permezz imblokk fit-tul tas-sintesi tal-gonadotrofina.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

warner chilcott  deutschland gmbh - testosterone - disfunzjonijiet sesswali, psikoloġiċi - - ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema, - livensa huwa indikat għall-kura ta ' l-hypoactive sesswali xewqa diżordni (hsdd) fin-nisa (menopause mezz kirurġikament indotti) bilateralment oophorectomised u hysterectomised li tirċievi estrogen konkomittenti terapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanquin plasma products b.v. - fattur tal-koagulazzjoni uman ix - hemofilja b - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja b (defiċjenza konġenitali tal-fattur ix).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

jenson pharmaceutical services limited - dextromethorphan, quinidine - manifestazzjonijiet ta 'mard newboliku - drogi oħra tas-sistema nervuża - nuedexta huwa indikat għat-trattament sintomatiku ta 'l-effett ta' pseudobulbar (pba) fl-adulti. l-effikaċja ġiet studjata biss f'pazjenti bi sklerożi laterali amjotrofika sottostanti jew sklerosi multipla.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mallinckrodt pharmaceuticals ireland limited - fibrinoġen uman, trombina umana - hemostasi, kirurġiċi - sustanzi kontra l-emorraġija - trattament ta 'sostenn fejn it-tekniki kirurġiċi standard mhumiex biżżejjed għat-titjib tal-emostasi. raplixa għandu jintuża f'kombinazzjoni ma approvat ġelatina sponża. raplixa huwa indikat fl-adulti minn 18-il sena.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - immunoloġiċi għall-għasafar - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rifjut ta 'graft - immunosoppressanti - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.